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ABSTRACT
Background: This article describes the qualitative methods used to
develop the EXAcerbation of Chronic Pulmonary Disease Tool (EXACT),
a new patient-reported outcome (PRO) instrument for evaluating fre-
quency, severity, and duration of exacerbations of chronic obstructive
pulmonary disease (COPD).
Methods: Focus groups and interviews were conducted in the United
States with COPD patients treated for exacerbations during the past
6 months. Participants were asked to describe exacerbation attributes,
care-seeking cues, and indications of progression and recovery. An itera-
tive process was used to identify themes in the data to inform instrument
content and structure. Cognitive debrieﬁng interviews were performed to
evaluate and revise the draft item pool. Experts in COPD, instrument
development, and clinical research participated in the process.
Results: Eighty-three subjects participated in elicitation focus groups or
interviews (n = 48); elicitation interviews with cognitive debrieﬁng
(n = 23), or cognitive interviews alone (n = 12). Mean age of the sample
was 65 years (SD = 10); 45% were male; mean FEV-1% predicted was
44% (SD = 16). Participants characterized exacerbations as a persistent
increase in the severity of respiratory symptoms and other systemic mani-
festations accompanied by a dramatic reduction in activity. Speciﬁc
attributes included shortness of breath, chest congestion, cough, sputum,
chest discomfort, feeling weak or tired, sleep disturbances, and concern or
worry. The diary card of 23 candidate items was debriefed in booklet and
electronic format.
Conclusions: Qualitative data from patients and input from experts
formed the basis of the EXACT’s structure and item pool, ready
for empirically based item reduction and reliability and validity
testing.
Keywords: COPD, diary cards, exacerbations, instrument development,
qualitative methods, respiratory symptoms, symptom assessment.
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized
by persistent airﬂow limitation with varying degrees of air sac
enlargement, airway inﬂammation, and lung tissue destruction.
The airﬂow obstruction characteristic of COPD is caused by a
mixture of small airway disease (obstructive bronchiolitis) and
destruction of the gas-exchanging surfaces of the lung (emphy-
sema), with the relative contribution of each varying from person
to person [1]. Chronic bronchitis, often the target of anti-
infective therapies for acute exacerbations (AECB), is a type of
COPD that is deﬁned by productive cough for 3 months or more
in at least two consecutive years. Cough and sputum production
may precede the development of airﬂow limitation; conversely,
some patients develop signiﬁcant airﬂow limitation without
chronic cough and sputum production [1]. Cardinal symptoms of
COPD are cough, sputum production, and breathlessness [2]
with systemic consequences of disease that include decondition-
ing, exercise intolerance, skeletal muscle dysfunction or fatigue,
anxiety, and depression among others [3].
The medical literature generally describes exacerbation as an
acute, sustained worsening of the patient’s underlying condition
of COPD from the stable state and beyond normal day-to-day
variability which may require a change in treatment [1,4,5].
These events are a major cause of morbidity and mortality in
COPD [6–11]. Given the substantial humanistic and economic
costs associated with exacerbations, reducing their frequency,
severity, and duration is of great interest to patients, providers,
and payers. This interest is reﬂected in the frequency with which
investigators study interventions for the treatment or prevention
of exacerbations, with occurrence and/or resolution serving as
inclusion criteria or as primary or secondary endpoints in clinical
trials [12–14].
Despite the importance of exacerbations in COPD, there has
been no standardized, reliable, or valid method for quantifying
these events in clinical studies [15]. To date, studies of exacerba-
tion frequency have used two methods of assessment: 1) event-
based, and 2) symptom-based [16–18]. The event-based method
deﬁnes exacerbation frequency based on health-care utilization,
i.e., clinic visits, emergency room visits, or hospitalizations, often
with a superimposed requirement of a change in treatment, gen-
erally oral steroids or antibiotics. Utilization events have also
been used as a proxy for severity, with unscheduled clinic or
emergency room visits rated “moderate” and those requiring
hospitalization labeled “severe” [5]. There are a number of prob-
lems associated with event-based deﬁnitions, including the bias
introduced by regional differences in health policy (resulting in
regions with liberal admission policies showing more frequent
and more severe exacerbations) and misclassiﬁcation bias
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because of failure to account for unreported events, estimated to
be as high as 50% to 70% [8,9,18–20]. An event-based deﬁnition
also fails to standardize change in the patient’s underlying con-
dition from their normal day-to-day variability, an essential
feature of an exacerbation. The symptom-based method for
deﬁning exacerbations assesses this change through a patient-
completed symptom diary card [4,8,21–23]. Unfortunately, there
is substantial variability in both content and structure of these
diaries across clinical studies, with little to no evidence of their
content validity or performance properties. This not only raises
questions about reliability and validity, but may also account for
some of the inconsistencies in ﬁndings across otherwise similar
study designs, and makes comparison of results across clinical
studies or trials virtually impossible.
Clinical trials evaluating the efﬁcacy of antimicrobial treat-
ment for acute exacerbations of COPD have used a test-of-cure
visit, generally at days 3 and/or 10, during which clinical inves-
tigators assess the subject’s health status, determine clinical
response, and recommend further treatment based on the indi-
vidual clinician’s subjective assessment and judgment. To date,
there have been no standardized measures for assessing the sever-
ity of patient symptoms at baseline or follow-up or for quanti-
fying the magnitude of change over time indicative of resolution.
A standardized patient-reported outcome (PRO) instrument for
assessing symptoms in AECB studies has been suggested in the
FDA’s Draft Guidance for Industry on Acute Bacterial Exacer-
bations of Chronic Bronchitis in Patients with Chronic Obstruc-
tive Pulmonary Disease [24].
Because the initial detection of an exacerbation originates
with symptoms which are known directly by the patient and
clinical assessments are based on patient report to the clinician, it
is logical and desirable for clinical studies of exacerbations of
COPD to gather reports directly from patients, through a PRO
measure. To ensure quality, enhance efﬁciencies, and facilitate
meta-analysis, it would be beneﬁcial for the ﬁeld to use a single,
standardized PRO measure with evidence of content validity and
known properties of reliability and validity. The Exacerbations of
Chronic Obstructive Pulmonary Disease Tool—Patient Reported
Outcomes (EXACT-PRO) Initiative is a program involving inter-
national experts in COPD, clinical research, instrument develop-
ment, and US Food & Drug Administration (FDA) regulatory
issues with unrestricted ﬁnancial support from multiple pharma-
ceutical sponsors in the development of a single PRO instrument,
known as the EXACT, to evaluate exacerbation outcomes in
international trials of COPD.
This article presents the methods and results of the qualitative
work that formed the basis of the EXACT. The purpose of this
qualitative work was to understand how patients describe exac-
erbations, including their essential attributes and indications of
onset, duration, and recovery; and to translate this understand-
ing into a PRO instrument to capture frequency, severity, and
duration of exacerbation in clinical studies of COPD. Figure 1a
shows a schematic representation with deﬁnitions of frequency,
severity, and duration of exacerbations as evaluated in preven-
tion trials; Figure 1b depicts severity and duration of exacerba-
tion as assessed in acute/anti-infective exacerbation treatment
trials.
Background
Qualitative research methods are essential to the development of
a PRO instrument, forming the basis for its content validity.
Content validity refers to the adequacy of an instrument to
measure what it purports to measure, reﬂected in the represen-
tativeness of the items and the methodological rigor with which
the instrument is constructed or formulated [25,26]. Qualitative
research is an inductive empirical method involving focus groups
or 1:1 interviews in which the words and phrases of the study
participants, recorded and transcribed, serve as the data [27–29].
Investigators apply systematic analytical methods to identify pat-
terns or clusters of information in the data and present the
ﬁndings in the form of themes and concepts. In the case of
the development of a new PRO instrument, these themes and the
words and phrases provided by study participants are used to
inform the overall structure of an instrument, including content
(questions or item stems, response options, and potential sub-
scale or domain structure), recall period, frequency and mode or
method of administration, and instructions for administration.
Cognitive debrieﬁng interviews are a speciﬁc type of qualitative
method designed to uncover problems in the social-cognitive
processes involved in completing an instrument, including difﬁ-
culties with comprehension or understanding of concepts and
terminology, problems knowing or remembering, and difﬁculty
selecting a response consistent with experience. Based on these
interviews, adjustments may be made in an instrument to
enhance validity and/or improve ease of administration [26,28].
For an instrument to assess exacerbations of COPD, qualitative
data from focus groups and interviews can provide a rich source
of information about patient terminology and descriptions of
these events, the manifestations or attributes that deﬁne them,
and the actions patients may or may not take when these events
occur to inform instrument development, while cognitive inter-
viewing provides a method for evaluating and adjusting the new
instrument as needed.
Prior to initiating qualitative work, a comprehensive review
of the literature was performed, including an evaluation of the
measures previously used to assess exacerbation frequency, sever-
ity and/or duration in clinical trials as well as the methods and
results of these trials. No single, standardized measure was used
and no publications describing development and validation of an
instrument for quantifying these outcomes was uncovered. Pub-
lished descriptions of diary cards used in clinical studies showed
consistency in some content areas, including assessment of the
respiratory symptoms of breathlessness, cough (frequency, sever-
ity), and sputum production (quantity), suggesting consensus
that these are essential features of exacerbation. Rating methods
for these attributes varied and included 4-point scales (none to
severe), ratings of discomfort with cough (none to very uncom-
fortable or unbearable), and asking patients to indicate whether
symptoms were more than usual (yes/no). Areas of content
inconsistency included questions about: chest tightness; night-
time awakenings; sputum color, quantity and thickness; feeling
weary, tired or faint; sore throat; nasal discharge or congestion;
and, fever.
Qualitative studies describing exacerbations from the
COPD patient’s perspective offered insight into patient percep-
tions of these events [30–32]. Results of these studies showed
that patients clearly understand the concept of exacerbation
and are able to identify and describe these events. The concern
they associate with exacerbations is reﬂected in the terminology
they use, including “crisis,” “attack” [31,32], and “frightening
change” [30], with panic and dread associated with their
onset [32]. Manifestations of an exacerbation described by
patients participating in these qualitative studies included
lower respiratory tract symptoms (breathing difﬁculty, changes
in phlegm, increased cough, difﬁculty coughing up phlegm),
upper respiratory symptoms (runny nose, sneezing), systemic
signs and symptoms (anorexia, exhaustion, feeling weak,
generally unwell, dizziness, sweating, cramping pain, and
“other” (“grey” color, headaches, and unable to speak),
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Figure 1 (a) Exacerbation Prevention Trial. (b) Acute/Anti-Infective Treatment Trial.
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and changes in daily activity (slower, difﬁculty performing)
[30,31].
The results of the literature review conﬁrmed the need for a
single, standardized measure with a core set of key attributes
indicative of an exacerbation of COPD and provided back-
ground information for the development of the study protocols
and data analyses that would form the basis for the new
instrument.
Materials and Methods
Design
This instrument development study used a qualitative research
design drawn from phenomenology and grounded theory [33].
The phenomenological approach emphasizes the “lived experi-
ence,” with participants recruited for their experience with the
phenomenon under study and interviewed to provide a detailed
account of this experience. Data are coded to characterize the
phenomenon, including its structure, core elements, and clusters
of categories comprising the experience [34,35]. Although
grounded theory is generally used to understand social pro-
cesses, this approach can be applied to instrument development
by drawing on its sampling and analytical methods. Participants
with varied experiences with the target phenomenon are inter-
viewed to explore its multiple dimensions, with analyses involv-
ing a constant comparison method with open, axial, and
selective coding. Themes identiﬁed in the initial coding can be
explored in follow-up interviews, with the entire process result-
ing in thematic descriptions of the phenomenon [36,37]. In this
study, the goals of data collection and analyses were to under-
stand participants’ experiences of exacerbations with an empha-
sis on the words and phrases used to describe key attributes and
the evolution and recovery process, and to translate these
descriptions into a measurement approach for quantifying the
frequency, severity, and duration of exacerbations in clinical
studies.
The qualitative methods included focus groups and inter-
views to elicit patient descriptions of the exacerbation experience
and cognitive debrieﬁng interviews to evaluate the draft instru-
ment. All groups and interviews involved participants with
COPD and a recent history of exacerbation. A team of interna-
tional pulmonary, clinical research, instrument development, and
regulatory experts provided consultation throughout the devel-
opment process. Two of the authors (PJ, SS) served as senior
clinical consultants, providing input on methodology, interpreta-
tion, and content and structure of the instrument. In addition,
two expert panel meetings were held to critique and discuss the
qualitative study methods and results, including the proposed
structure of the new PRO instrument and the content of its item
pool. Panelists included the senior clinical consultants (PJ, SS),
members of the EXACT-PRO Study Group (see acknowledg-
ments), and one individual from each of the following FDA
divisions: Study Endpoints and Labeling (SEALD), Pulmonary,
Anti-Infective, and Special Pathogen. Representatives from each
sponsor company and additional members of the FDA attended
the meetings as observers and were invited to ask questions and
comment during the proceedings.
Sample
To maximize representation, participants with COPD were
recruited through pulmonary and primary care physician ofﬁces
in four states in diverse regions of the United States: Arizona,
Florida, Maryland, and Michigan. Inclusion and exclusion crite-
ria were consistent with those used in pharmaceutical trials
evaluating the efﬁcacy and safety of preventive and anti-infective
therapies for exacerbations of COPD. Inclusion criteria were as
follows: age greater than or equal to 40 years; smoking for at
least 10 pack/years; current medical diagnosis of COPD and/or
chronic bronchitis, with the latter deﬁned as cough and sputum
production for at least 3 months in 2 consecutive years with or
without airﬂow obstruction [1]; willing and able to provide
written informed consent; able to participate in a group discus-
sion; and able to speak and read English. All participants had a
history of exacerbation in the past 6 months and a subset of
patients had a history of a recent exacerbation, identiﬁed within
10 days of a clinic call, clinic visit, emergency room visit, or
hospitalization for a medically conﬁrmed worsening of the
patient’s condition, from the stable state and beyond normal
day-to-day variation, that was acute in onset and necessitated a
change in regular medication.
Exclusion criteria were as follows: current diagnosis of
asthma with no obstructive disease (post bronchodilator >80%;
FEV-1/FVC70%), and no chronic bronchitis; current diagnosis
of clinically relevant bronchiectasis; and, a concurrent medical or
psychiatric condition or cognitive impairment that, in the inves-
tigator’s opinion, would affect participation in the study.
During enrollment and following consent, participant’s stable
state pulmonary function test (PFT) values provided by the clini-
cal site were reviewed to assure representation across varying
levels of airway obstruction consistent with the target popula-
tion. Speciﬁcally, the ratio of forced expiratory volume in one
second to forced vital capacity (FEV-1/FVC) and FEV-1 as a
percentage of predicted value were examined by Global Initiative
for Chronic Obstructive Lung Disease (GOLD) [1] severity clas-
siﬁcation (see Table 1), with adjustments made during recruit-
ment to make certain the ﬁnal sample included a distribution of
patients from Stages 2 and 3, with some representation from
Stage 4.
Procedures
Qualitative data were collected in three rounds over a 7-month
period (February through August, 2006). Round 1 (n = 48)
involved focus groups and interviews designed to elicit concepts
related to patient experiences, terminology, and attributes of
exacerbation that would inform instrument development. This
round included participants who had experienced an exacerba-
tion in the previous 6 months (n = 40) or were within 10 days of
an exacerbation (n = 8). Data from stable, nonexacerbating
patients were collected through four focus groups (n = 34);
supplemented by two 2:1 interviews (two participants, 1 inter-
viewer, n = 4) and two 1:1 interviews (n = 2). The opportunity to
interview participants in a 2:1 and 1:1 setting arose during focus
group scheduling based on subject availability and provided an
opportunity to assess respondent differences by method of data
collection. Interviews with patients identiﬁed within 10 days of
an exacerbation, all 1:1, were conducted to assess whether any
concepts were missed because of participant recall.
Data were collected and analyzed for themes and subthemes
until saturation was reached, deﬁned as at least two focus group
discussions and two interviews during which participants
spontaneously introduced no new themes, beyond those identi-
ﬁed previously, documented in the form of a saturation grid.
Saturation was reached during Round 1, with the data used to
inform the instrument’s content, structure, and draft item pool.
Methods and results were presented and discussed with experts
during the ﬁrst expert panel meeting.
To increase ethnic diversity of the sample, a second round of
interviews were conducted. Round 2 involved 1:1 semi-structured
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concept elicitation interviews with participants of African Ameri-
can and Hispanic descent (n = 23) to assess consistency in themes
and terminology, identify any new themes, and re-assess satura-
tion. Following the elicitation component of the interview, each
participant took part in an evaluative cognitive debrieﬁng inter-
view of the draft item pool in paper–pen booklet format. In
addition to the 23 participants, 3 Caucasian subjects participated
in evaluative cognitive interviews alone. Methods and results of
the Round 2 interviews were presented and discussed with experts
during the second panel meeting.
Round 3 of the study involved cognitive debrieﬁng interviews
with COPD patients (n = 9) using the ﬁnal item pool pro-
grammed into a personal digital assistant (PDA). These inter-
views also provided an opportunity to conduct a usability
assessment with the device to gain insight into speciﬁc participant
or site training that might be required during the implementation
of the ensuing item reduction and validation study.
Protocols were approved by an appropriate institutional
review board (IRB) and consent was obtained from each partici-
pant prior to any discussion of study-related materials. Trained,
experienced interviewers conducted all focus groups and inter-
views using semi-structured interview guides designed to facili-
tate discussion and optimize consistency across groups and
individuals. A trained assistant was present during focus groups
to take notes and facilitate discussion as needed, and an experi-
enced researcher observed the proceedings and provided recom-
mendations to the facilitator and assistant as needed during
planned breaks. Group discussions lasted approximately 2 hours.
Interviews with participants within 6 months of an exacerbation
were performed in clinic ofﬁces and lasted one to two hours.
Participants who were identiﬁed within 10 days of a clinic visit
for exacerbation were interviewed by telephone or in-person, as
they preferred, using a focused interview guide to minimize
patient burden. These interviews lasted approximately 20
minutes and addressed the patients’ immediate experiences with
their current exacerbation, including indications of onset, sever-
ity, and recovery. All groups and interviews were audio-recorded
and transcribed for analyses.
Measures
To characterize the sample, participants completed a set of self-
administered questionnaires at the conclusion of their focus
group or interview, including a sociodemographic questionnaire,
the Modiﬁed Medical Research Council (MMRC) dyspnea rating
scale, and the St. George’s Respiratory Disease Questionnaire
(SGRQ). The MMRC ranges from 1 (“no breathlessness except
with strenuous exercise”) to 5 (“too breathless to leave the
house”) [38,39]. The 76-item SGRQ assesses the impact of res-
piratory disease on health status using a total score and three
subscale scores (Symptoms, Activity, and Impacts) [40]. Scores
range from 0 to 100, where higher scores indicate poorer health
status. For those participating by telephone (n = 7), question-
naires were completed at home and returned by mail. Clinical
data, including medical diagnosis and PFT values, were provided
by the clinical site.
Analyses
Sample sociodemographic and clinical characteristics were
summarized descriptively using SAS Version 9.1.3. The qualita-
tive analysis software program Atlas.ti version 5.0 was used to
Table 1 Sample demographic and clinical characteristics
Characteristics
EXACT development Further development with debrieﬁng of draft items Final debrieﬁng
Total sample
(N = 83)
Focus groups
(N = 40)
1:1 interviews
(N = 8)*
1:1 interviews
and cognitive
debrieﬁng (N = 23)
Cognitive
debrieﬁng (N = 3)
Cognitive
debrieﬁng with
PDA (N = 9)
Demographic
Age, mean (SD) 68.4 (7.7) 65.8 (8.0) 58.3 (12.0) 65.3 (6.1) 69.1 (5.9) 65.3 (9.7)
Gender, male n (%) 15 (38%) 2 (25%) 13 (57%) 1 (33%) 6 (67%) 37 (45%)
Race/ethnicity n (%)
White 40 (100%) 7 (88%) 0 (0%) 3 (100%) 9 (100%) 59 (71%)
Hispanic or Latino 0 (0%) 0 (0%) 11 (48%) 0 (0%) 0 (0%) 11 (13%)
Black or African American 0 (0%) 1 (13%) 12 (52%) 0 (0%) 0 (0%) 13 (16%)
Clinical
COPD diagnosis—years since,
mean (SD)
5.8 (4.1) 6.1 (2.5) 11.4 (7.5) 18.0 (13.7) 9.8 (4.7)‡ 8.3 (6.4)
Spirometry†, mean (SD)
FEV†-1(L) 1.2 (0.4) 0.9 (0.2)‡ 1.0 (0.4) 1.0 (0.2) 1.3 (0.5) 1.1 (0.4)‡
FEV-1% predicted 48.6 (14.3) 34.7 (10.9)‡ 41.0 (18.1) 39.3 (9.9) 43.4 (17.1) 44.4 (15.8)‡
GOLD§ 1 (FEV-1 80%
predicted)
2 (5%) 0 (0%) 0 (0%) 0 (0%) 1 (11%) 3 (4%)
GOLD 2 (FEV-1 >50 and
<80% predicted)
22 (55%) 1 (13%) 2 (9%) 0 (0%) 0 (0%) 25 (30%)
GOLD 3 (FEV-1 >30% and
<50% predicted)
14 (35%) 5 (63%) 10 (44%) 3 (100%) 5 (56%) 37 (45%)
GOLD 4 (FEV-1 >30% and
<50% predicted + chronic
respiratory failure)
2 (5%) 2 (25%) 11 (48%) 0 (0%) 3 (33%) 18 (22%)
MMRC Dyspnea score, n (%)¶
0–1 2 (5%) 1 (13%) 7 (31%) 1 (33%) 6 (67%) 17 (21%)
2 12 (30%) 3 (38%) 6 (26%) 1 (33%) 2 (22%) 24 (29%)
3–4 25 (63%) 4 (50%) 8 (35%) 1 (33%) 1 (11%) 33 (47%)
SGRQ Total Score, Mean (SD) 52.5 (18.0) 51.7 (20.9) 63.9 (18.0) 67.8 (29.8) 43.7 (13.9) 54.7 (19.1)
*Patients had diagnosis of an exacerbation within the last 10 days at recruitment; all other groups had a diagnosis in the last 6 months.
†Stable state; FEV-1: forced expiratory volume in one second.
‡Data missing for 1 patient.
§Global Initiative for Chronic Obstructive Lung Disease (GOLD).
¶As reported by the patient.
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organize the transcript data for coding and analyses. Focus group
moderators and interviewers (KH, JP) reviewed and cleaned the
data prior to analyses.
For data gathered during Round 1, four team members,
including the two focus group moderators and interviewers (KH,
JP) and two experienced researchers (NKL, TW), examined the
transcript data and developed a coding dictionary of themes and
subthemes. Two team members (KH, JP) used this dictionary to
code independently the data. When new themes not included in
the initial coding dictionary were identiﬁed they were discussed
with the other team members, the coding dictionary was
updated, and the data were reanalyzed to ensure that the new
theme was fully captured. Coded data were compared across
coders and the few discrepancies were resolved through consen-
sus among the research team. The ﬁnal, coded data set was then
stratiﬁed and examined across gender and disease severity
(GOLD stage) to evaluate representativeness of themes and sub-
themes and assure applicability of instrument content and struc-
ture across these groups.
The item pool, response options, and recall period for the
instrument were developed based on themes and subthemes iden-
tiﬁed in the qualitative data, with the participants’ words and
phrases used to inform wording. Items were developed using an
iterative process of development, review, revision, discussion,
and revision, with reference back to the qualitative data to
inform decision-making. After the initial set of draft items was
developed, an item tracking matrix was created to document the
nature and rationale for revisions. Senior clinical research experts
(PJ, SS) participated in the review/revision process and an expert
in PRO translation from the EXACT-PRO Study Group (SE)
provided comments on cultural and linguistic issues associated
with various words and phrases used in the draft item pool.
Qualitative data gathered during the elicitation interviews con-
ducted during Round 2 were examined for new terminology,
descriptions, and/or themes that should be used to revise the
initial draft item pool.
Results of the cognitive debrieﬁng interviews conducted
during Rounds 2 and 3 were examined for insight into partici-
pant interpretation of the items, making certain that understand-
ing was consistent with the intent. Revisions were based on
participant comments with consideration given to data gathered
during elicitation focus groups and interviews and input from
experts.
Results
Sample
Demographic and clinical characteristics of the study sample
overall and by data collection round are shown in Table 1. Of the
83 participants, 45% were male, 71% self-identiﬁed as white,
13% Hispanic or Latino and 16% Black or African American.
Mean FEV-1% predicted for the sample was 44% with partici-
pants distributed across GOLD stages 2, 3, and 4.
Patient Description of Exacerbation
Three major themes and ﬁve subthemes were identiﬁed in the
data: 1) deﬁnition; 2) attributes (subthemes: respiratory and sys-
temic); and 3) progression (subthemes: awareness, cues to care-
seeking, recovery indicators). Themes and subthemes were
consistent across focus groups and interviews and across ethnic-
ity, gender, and GOLD stage. Descriptions of the themes and
subthemes each are as follows:
Deﬁnition. Participants described an exacerbation as an “event”
or “episode,” characterized by an increase in the severity of
respiratory symptoms and other systemic manifestations that
occur over a two-to-three day period and is accompanied by a
marked reduction in activity. They contrasted the persistence of
the event with one or two “bad days” and with acute situations
of breathlessness or cough for which relief occurs within a very
short period of time.
Attributes. Table 2 presents the speciﬁc attributes participants
ascribed to exacerbations with sample quotations. Two attribute
themes were identiﬁed in the data: respiratory symptoms and
systemic manifestations. Respiratory symptoms included cough,
sputum production, chest discomfort, and difﬁculty breathing.
Participants described cough in terms of chest congestion and
frequency.Many described chest congestion that could progress to
the point of “feeling full.” Frequency of the cough ranged from
every now and then to every two or three minutes to coughing all
the time without a break. Participants used the terms mucus,
phlegm, or “stuff”when referring to sputum, describing it in terms
of volume, persistence, and color. Change in sputum color was
used as a cue to care seeking, with participants using descriptive
terms indicating a progression from “clear” to “yellowish,
orange” to “smoky green,” and ﬁnally to “brownish, dark green,
lime green.” Chest discomfort was characterized as feeling hurt or
sore in the chest or ribcage, often attributed to severe or continu-
ous coughing. Participants used the terms “difﬁculty breathing,”
“unable to breath,” “shortness of the breath” and “couldn’t
breathe” to characterize breathlessness. Difﬁculty breathing was
described in terms of general severity, “not getting enough air in”
or “extreme shortness of breath,” as well as being related to
activity, “I was short of breath doing activities where I wasn’t
normally short of breath” or “I had to gasp for air every few
steps.” Participants often described situations during an exacer-
bation in which they were short of breath during an activity they
normally did not associate with breathlessness.
Systemic manifestations of exacerbation included limitations
of activity, feeling weak or tired, sleep disturbance and feeling
concerned or worried. Participants described a full range of
activity limitation with exacerbations, often associated with
breathlessness and feeling weak or tired. Activity limitations
included problems performing usual activities around the home
or difﬁculty performing basic activities of daily living, such as
morning care or simple meal preparation. Severe episodes made
walking across the room or getting out of bed almost impossible.
Weak and tired was described in terms of: “Low energy, didn’t
want to do anything, lethargy, malaise, or whatever the term is”;
“It cuts you at the knees.” Sleep disturbances varied, from sleep-
ing all the time, to severe disruption at night often attributed to
cough and/or breathing difﬁculty. Worry or concern about their
health state included feeling tense, edgy, scared, and worried.
Progression. The data revealed three subthemes related to pro-
gression: an awareness of change in their condition, cues to
seeking care, and indicators of recovery. Table 3 shows sample
quotations for these subthemes. At the onset of an event, partici-
pants noticed a worsening of one or more respiratory symptom,
such as an increase in cough frequency and/or more labored
breathing and/or a change in sputum production that lasted
beyond one or two “bad days.” This change together with one or
more systemic attributes led to an awareness that “something was
not right” and the conclusion that they were having an “episode.”
The decision to seek care was prompted by any of several factors,
including a change in sputum color, extreme breathlessness,
anxiety, or the continued persistence of their worsened state: “My
breathing was starting to get a tiny bit labored . . . it progressively
got worse and worse and worse,” and the decision they would not
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be able to self-treat or bear it out: “I couldn’t take it anymore. I
couldn’t breathe. I couldn’t walk through the house.” Partici-
pants felt they were recovering from an episode when they noticed
consistent improvement in their respiratory symptoms, more
normal sleep patterns, feeling less weak or tired, and an easing of
their concern or worry, followed or accompanied by a gradual
resumption of their usual daily activity. Recovery was often
subtle; and with thought, participants indicated they knew they
were “out of it” when their conﬁdence and ability to walk outside
or go to the store had returned.
All of the participants described events or episodes during
which they did not contact a health care professional. The choice
to report events depended on duration and severity of the
attributes of an exacerbation and other activities going on in
their lives.
Instrument Structure and Item Pool
Existing literature, expert knowledge of the condition, and the
qualitative data from experienced patients all supported the use
of a daily diary to capture frequency, severity, and duration of
exacerbations of COPD. Given the typical age of patients with
COPD, the nature and severity of this condition during stable
and acute states, and the participant’s description of the impact
of exacerbations on their functioning, it was clear that the instru-
ment should be simple and easy to complete with short, crisp
questions and clear response options. One diary approach con-
sidered was ecologic momentary assessment, in which respon-
dents would be signaled to complete the instrument electronically
at random intervals throughout the day [41]. This approach was
deemed inappropriate because of the presence of multiple items
that together would require several minutes to complete, the 6-to
12-month duration of prevention trials, and the altered sleep/
wake patterns characteristic of exacerbations. A second option
was a morning and evening diary with participants assessing
their symptoms at both time periods. This was considered incon-
sistent with the qualitative data and item content which was
heavily dominated by descriptions of daytime attributes, indicat-
ing a twice daily diary would be unnecessarily burdensome for
participants in long-term or acute intervention trials.
A once daily assessment method was selected, with
participants completing the diary at the close of each day, just
Table 3 Patient descriptions of exacerbation progression
Awareness/onset
Increase cough Change in sputum More labored breathing Combination
• I noticed a tickling, coughing pretty
much.
• All of a sudden I built up
congestion.
• Thick and I knew I was in trouble.
• It [sputum] seemed to be more
severe, more often, and I’d cough
up a white phlegm but it was real
thick.You have a hard time even
getting it out of your mouth.
• For about a couple of weeks, it
kept getting . . . I noticed my
breathing wasn’t coming up to par.
• It gets to the point where you
cannot breathe.
• I just started having a lot more
coughing and more difﬁculty
breathing doing everyday things
that I wouldn’t normally have a
problem with.
• Probably . . . ﬁrst . . . is the no
energy and the shortness of breath
then followed by the phlegm.
Cues to seek care
Sputum color Extreme breathlessness Anxiety Energy
• I began coughing yellow.When that
happens the doctor says to you
that’s the infection.
• I went to the doctor because I was
coughing up yellow.That’s a red
ﬂag for me.
• I know when it’s green. I’ve got to
go somewhere.
• When I’m sick it’s brownish.
• When you’re really having trouble
breathing, you go to the doctor.
• After a few days of having trouble
breathing.
• The more I saw that I had
shortness of breath, that triggered
me calling the doctor.
• I couldn’t breathe anymore.
• It was just getting harder and
harder to breathe, and I was really
scared.
• I woke up coughing, choking, very
short of breath. It scared the hell
out of me.
• It just scared me. It scared me not
being able to cough and breathe
and feel very vulnerable at that
time.
• It makes you worry more.
• If it’s more than a week, then I
really begin to be concerned.
• I go [to the doctor] for the lack of
energy even if I didn’t have that
panicky feeling.
• I say wow, I didn’t do nothing but
I’m tired.
• I was weak and tired. I couldn’t
breathe. I’d been laying down.
Recovery
Cough Difﬁculty breathing Sleep Activities
• Coughing less and it’s getting
clearer.
• Not coughing as much . . .
• Easing up of the coughing . . .
• The coughing stopped, not stopped
completely, but it went back to
normal.
• The cough was gone.
Sputum
• I will measure my days by “was it a
ﬁve handkerchief day? Or am I
down to only a two handkerchief
day”?
• It was coming up easier, and not as
difﬁcult. It would pop up better.
The color kept getting lighter.
• The breathing got better ﬁrst.
• The ﬁrst thing I noticed probably
was the easing of the breathing.
• I could just feel it every day that
what would take me ﬁve minutes
one day would take me three
minutes the next day, and pretty
soon my breathing was back to
normal.
• As the week progressed, I could
breathe more normally.
• My breathing was easier, and I felt
better.
• I started breathing a little better.
• I started sleeping better.
• I sleep all the way through the
night now.
Tired or weak
• I didn’t feel quite as tired.
• Basically, I’m able to stay out of
bed.
Psychological state
• I felt like now I can sit and enjoy
an evening with my husband
instead of thinking I’m going to fall
apart.
• I wake up feeling better and my
mental attitude is very positive.
• I felt secure enough to take a
shower without someone being
there.
• I was able to brush my teeth
without getting out of breath or
coughing in between.
• I was able to do things . . . make
tea for myself, able to walk to the
bathroom by myself and not having
to stop and feel like I’m going to
die.
• I went [out] for a few hours, and
gradually I went up to my ten
hours a day.
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prior to bedtime, reﬂecting back on their day and providing
an overall rating for each of the attributes assessed. There is
empirical evidence suggesting a close correspondence between
end-of-day assessment and aggregated momentary measures
for symptoms of pain and fatigue [42], and this approach
would be simpler to complete over long periods of time and
during acute illness, thereby enhancing data quality, including
compliance.
The instrument was drafted as a daily diary with a pool of 23
candidate items and formatted into an easy-to-read paper–pen
questionnaire booklet for use during the ﬁrst set of cognitive
debrieﬁng interviews (Round 2). During these interviews, partici-
pants were asked about their interpretation of the items and how
they selected their responses, with speciﬁc interest in the
approach they used to rate their symptoms for the day. Subjects
easily reﬂected back over the day as they rated each symptom,
selecting the response that best represented their experiences that
day. They were also asked to describe situations in which they
would assign a higher or lower severity rating based on the day’s
experience, responding easily to this query. Participants con-
ﬁrmed results of the existing data related to the day-to-day
variability of symptoms, adding that the items were able to
capture this variability. Based on input from these participants
and discussion during the second expert panel meeting, adjust-
ments were made in the draft item pool and recorded in the
item-tracking matrix.
Given the design of the daily diary card and increasing evi-
dence of the superiority of electronic diaries (e-diaries), consid-
eration was given to administration of the measure using a
personal digital assistant (PDA) in the subsequent item reduction
and validation study. Electronic diaries (e-diaries) have a number
of advantages of over paper diaries, including greater data
quality, data management efﬁciency and improved patient com-
pliance with rates reported to be as high as 83 to 94% [43–48].
There was also evidence to suggest that older adults with chronic
health conditions have successfully used e-diaries in clinical
studies, including international trials [43,44]. The Tungsten E2
was selected for its ease of use, clear display, screen size enabling
the item stem and response option to appear on one screen
without need for scroll bars, and simple navigation through
tapping, all features consistent with recommendations for older
adults [49]. The 23 revised items were programmed into the
device for the ﬁnal debrieﬁng interviews (Round 3) and as a way
to pilot test the device.
Following Round 3, one of two conceptually redundant items
was dropped and another was split into two items for added
clarity. Observing the participants with the PDA, none had any
difﬁculty using the device with minimal instruction. All reported
that it was easy to use, expected it would take less time to
complete than the diary booklet, and stated they would not have
a problem using the device in a 6-to 12-month study. Eight of the
nine participants expressed a clear preference for the PDA over
the booklet with the ninth reporting neutrality.
A preliminary conceptual framework showing the key
domains of exacerbation, sample content of the items, and
number of items in the ﬁnal item pool is provided in Figure 2. At
this point, the 23-item e-diary was considered ready for empiri-
cally based item reduction with performance testing of the ﬁnal
instrument, including an evaluation of its dimensionality, factor
structure, reliability, validity, and responsiveness.
Respiratory Symptoms
Cough
Sputum
Chest Discomfort
Additional Attributes
1. Chest congestiona
2. Cough frequencyb
3. Mucus when coughinga
4. Difficulty with mucusa
5. Color of mucusb
6. Chest discomforta
7. Chest hurta
8. Chest tighta
Difficulty Breathing
9. Breathlessa
10. How breathlessb
11. Short of breath sittinga
12. Difficulty breathing sittinga
15. Short of breath with personal carea
17. Short of breath with indoor activitya
19. Short of breath with outdoor activitya
Recall:  “Today” for each item
Response Options: a 5-point scale: Not at all to Extremely
b 5-point scale: Other 
Activity Limitation
13.   How activea
14.   Usual personal careb
16.   Usual indoor activitiesb
18.   Usual outdoor activitiesb
Tired or Weak
20.   Tired or weaka
Psychological State
23.   Scared or worrieda
Sleep Disturbance 21.   Sleep disturbeda
22.   How much sleepb
Figure 2 Preliminary Conceptual Framework for the 23-Item Pool.
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Discussion
This study was conducted as the ﬁrst phase of the multiphase
EXACT-PRO Initiative to develop a new instrument for stan-
dardizing PRO assessment of exacerbations of COPD. Focus
groups and interviews were conducted with patients who had
experienced exacerbations of COPD using enrollment criteria
similar to those used in preventive and acute/anti-infective
therapy trials to make certain the content and structure of the
instrument was consistent with patient-reported descriptions of
these events. International experts in pulmonology and clinical
research participated in the process to assure content validity
from a medical perspective, while an instrument development
and a translation expert contributed to structure, wording, and
format. Cognitive debrieﬁng interviews ascertained that partici-
pants interpreted the items as intended, while results of usability
assessment of the PDA suggested the device was easy to use with
relatively little instruction.
Participant descriptions of exacerbations of COPD and the
characteristic features of these events were consistent with clini-
cal deﬁnitions of a sustained worsening in the patient’s condition
beyond normal day-to-day variability that is acute in onset and
may necessitate a change in regular medication [1,4,5]. Partici-
pants added clarity to this deﬁnition by characterizing the wors-
ening as either acute or gradual, with the onset lasting several
days, thereby differentiating exacerbations from one or two “bad
days” that are characteristic of their day-to-day variability. Par-
ticipants also described changes in self-care that included greater
use of rescue medications and a reduction in activity, consistent
with results of the Kessler et al. [31] study in which participants
described taking additional medication or resting as part of their
exacerbation self-management.
Patient symptom descriptions were generally consistent with
those described in previous qualitative work and offered addi-
tional clarity related to day-to-day variability, and speciﬁc
attributes of exacerbation, severity, and progression. Participants
in the present study not only described increased breathlessness,
cough, and sputum production with exacerbation, but provided
detailed descriptions of chest discomfort and systemic manifes-
tations of these events, including feeling weak or tired, sleep
disturbance, and feeling worried or concerned, all associated
with a dramatic reduction in activity, minimal basic activities of
daily living and prohibiting instrumental activities of daily living.
This set of symptoms extends the traditional symptom triad of
breathlessness, cough, and sputum production characteristic of
COPD that serve as the common core of previous exacerbation
diaries. The additional attributes assessed in the new measure
reﬂect the patient’s experience with exacerbations and may con-
tribute to greater measurement precision.
The fact that the participants described experiences
characteristic of an exacerbation that they did not report to a
health-care provider is consistent with quantitative studies of
unreported events [9,10,18–20]. These results support previous
suggestions that exacerbation frequency in COPD has been
underestimated and that the efﬁcacy of treatment may be under-
stated when this outcome is deﬁned by health care utilization.
Conclusion
This article described the methods and results of the ﬁrst
phase of the EXACT-PRO Initiative designed to develop a
standardized PRO measure for assessing the frequency, severity,
and duration of exacerbation in clinical studies of COPD. To
address content validity, the EXACT’s structure and pool of 23
candidate items were based on data gathered through focus
groups and interviews and cognitive debrieﬁng interviews
involving patients with COPD with a recent history of exacer-
bation. Clinical research, instrument development, and transla-
tion experts provided input throughout the development
process. Based on this work, the EXACT-PRO Initiative moved
into Phase II, a prospective study of exacerbating and stable
patients designed to reduce the number of items and test the
ﬁnal instrument, known as the EXACT, for validity, reliability,
and responsiveness.
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